DDInter350 DDInter1355
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin. Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer.[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer. Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin&reg;.
Chlorambucil {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Chlorambucil {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Chlorambucil {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} (Compound) binds {v} (Gene) SLC22A3
SLC22A3 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Chlorambucil {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Chlorambucil {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Oxaliplatin
Chlorambucil {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is associated with {v} (Gene) ATP7B
ATP7B {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Floxuridine
Floxuridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Chlorambucil {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Chlorambucil (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Oxaliplatin (Compound)
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Chlorambucil (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Chlorambucil (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan (Compound) binds SLC22A3 (Gene) and SLC22A3 (Gene) is bound by Oxaliplatin (Compound)
Chlorambucil (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Chlorambucil (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Oxaliplatin
Chlorambucil (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is associated with ATP7B (Gene) and ATP7B (Gene) is bound by Oxaliplatin (Compound)
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Chlorambucil (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Paclitaxel (Compound) and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin